Evidence map›Paper›PMID 29316798›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2018

Regulation of mitophagy by the ubiquitin pathway in neurodegenerative diseases.

Shyamal Desai, Meredith Juncker, Catherine Kim

Open access · greenAbstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Mitophagy, Mitochondrial Homeostasis, and Cell Fate.Frontiers in cell and developmental biology · 2020
    Review
  16. Article
  17. Review
  18. Evaluation of Congo Red Staining in Degenerating Porcine Photoreceptors In Vitro: Protective Effects by Structural and Trophic Support.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shyamal DesaiDepartment of Biochemistry and Molecular Biology, LSUHSC-School of Medicine, New Orleans, LA 70112, USA.
Meredith JunckerDepartment of Biochemistry and Molecular Biology, LSUHSC-School of Medicine, New Orleans, LA 70112, USA.
Catherine KimDepartment of Biochemistry and Molecular Biology, LSUHSC-School of Medicine, New Orleans, LA 70112, USA.
Louisiana State University Health Sciences Center New Orleans · US

Funding

Deregulation of the Ubiquitin/26S Proteasome Pathway in AT cells: Role of ISG15R21NS060960 · NINDS · LSU HEALTH SCIENCES CENTER · PI DESAI, SHYAMAL D · 2008 to 2009
$342k
NINDS NIH HHS R21 NS060960
6 · The paper itself

Abstract

Mitophagy is a cellular process by which dysfunctional mitochondria are degraded via autophagy. Increasing empirical evidence proposes that this mitochondrial quality-control mechanism is defective in neurons of patients with various neurodegenerative diseases such as Ataxia Telangiectasia, Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. Accumulation of defective mitochondria and the production of reactive oxygen species due to defective mitophagy have been identified as causes underlying neurodegenerative disease pathogenesis. However, the reason mitophagy is defective in most neurodegenerative diseases is unclear. Like mitophagy, defects in the ubiquitin/26S proteasome pathway have been linked to neurodegeneration, resulting in the characteristic protein aggregates often seen in neurons of affected patients. Although initiation of mitophagy requires a functional ubiquitin pathway, whether defects in the ubiquitin pathway are causally responsible for defective mitophagy is not known. In this mini-review, we introduce mitophagy and ubiquitin pathways and provide a summary of our current understanding of the regulation of mitophagy by the ubiquitin pathway. We will then briefly review empirical evidence supporting mitophagy defects in neurodegenerative diseases. The review will conclude with a discussion of the constitutively elevated expression of ubiquitin-like protein Interferon-Stimulated Gene 15 (ISG15), an antagonist of the ubiquitin pathway, as a potential cause of defective mitophagy in neurodegenerative diseases. Impact statement Neurodegenerative diseases place an enormous burden on patients and caregivers globally. Over six million people in the United States alone suffer from neurodegenerative diseases, all of which are chronic, incurable, and with causes unknown. Identifying a common molecular mechanism underpinning neurodegenerative disease pathology is urgently needed to aid in the design of effective therapies to ease suffering, reduce economic cost, and improve the quality of life for these patients. Although the development of neurodegeneration may vary between neurodegenerative diseases, they have common cellular hallmarks, including defects in the ubiquitin-proteasome system and mitophagy. In this review, we will provide a summary of our current understanding of the regulation of mitophagy by the ubiquitin pathway and discuss the potential of targeting mitophagy and ubiquitin pathways for the treatment of neurodegeneration.

Indexed as

MitophagyCytokinesHumansNeurodegenerative DiseasesProteasome Endopeptidase ComplexProtein Aggregation, PathologicalUbiquitinUbiquitinsCytokinesISG15 protein, humanProteasome Endopeptidase ComplexUbiquitinUbiquitinsMitochondrialneurodegenerationpathologypost-translationalproteasomeproteolysis

Identifiers

PMID29316798
PMCPMC5882017
OpenAlexW2783967054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.